As a result, remdesivir may never be successfully commercialized. For those who are unfamiliar, Gilead Sciences is a U.S.-based corporation that creates and commercializes pharmaceutical products.
He is also on the board of Galapagos NV, Pharmaceutical Manufacturers Association of America, Flatiron Health, Inc. and Shanghai Roche Pharmaceuticals Ltd. Research, iteration and perseverance have to be constant factors in scientific progress. Prior to Gilead, Daniel served as the Chief Executive Officer of Roche Pharmaceuticals. O'Day will join Gilead at a critical moment for the three-decade-old biotech. Last week’s news on dexamethasone appears to further support the study of complementary approaches for treating COVID-19. And yet, we still have some way to go in exploring the full potential of remdesivir to help against COVID-19.
We are committed to doing everything we can to help with this pandemic, while ensuring we are prepared for the next. Dexamethasone is a steroid that potentially reduces the body’s inflammatory response to the virus. Our scientists will stay focused on optimizing the manufacturing process, and we will continue to collaborate globally to ensure sufficient worldwide supply. This authorization is temporary and may be revoked, and does not take the place of the formal new drug application submission, review and approval process. Gilead will do all it can to help drive that progress by exploring the full potential of remdesivir.As part of our aim to benefit as many patients as possible, we are focused on ensuring sufficient supplies of remdesivir and enabling access. O’Day is the CEO of Gilead since March 2019. In particular, it specializes in antiviral drugs for influenza, HIV, hepatitis B, and hepatitis C, meaning that it has been a subject of interest for the news in recent times. The totality of these data shows that remdesivir has the potential to be of meaningful benefit to patients with COVID-19 and offers important hope. Remdesivir is now being used to treat patients through emergency use authorizations and other access programs around the world. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. Our commitment to remdesivir will continue now as we explore its full potential in the hope of helping many more patients with COVID-19.
Science & Medicine At the same time, our broader, ongoing research in emerging viruses continues. In recent years, our scientists built up a library of compounds – one of which was remdesivir – that could potentially be used against future viruses. As we go forward, we will work to ensure that remdesivir is accessible and affordable to governments around the world. We now expect to have more than two million remdesivir treatment courses manufactured by the end of the year and many millions more by 2021. In the later stages, the body’s inflammatory response may cause some of the most life-threatening aspects of the disease.
In the NIAID study, remdesivir shortened recovery time by an average of four days and in the SIMPLE study of moderately ill patients (those in hospital but not requiring oxygen), individuals on a five-day course of remdesivir had better clinical outcomes than those receiving standard of care.
Remdesivir is an investigational drug that has not been approved by the FDA for any use, and its safety and efficacy has not been established for the treatment of COVID-19.
In addition to extending our focus to earlier treatment and combinations, our next wave of studies of remdesivir will include Our best hope of beating COVID-19 is with a set of tools at our disposal: complementary therapeutics, effective vaccines and widespread testing. Product sales, which soared between 2014 and 2016 on the back of a slate of highly effective medicines for hepatitis C, have fallen rapidly as that market has matured and become more competitive. We have been keen to explore how remdesivir might work when combined with anti-inflammatory agents, particularly in the most severely ill patients.
If Gilead is unable to sufficiently scale up manufacturing of remdesivir in the currently anticipated timelines, Gilead may be unable to meet global supply needs.